Ra Pharmaceuticals (NASDAQ:RARX) Downgraded by BidaskClub to Hold

Share on StockTwits

BidaskClub cut shares of Ra Pharmaceuticals (NASDAQ:RARX) from a buy rating to a hold rating in a report released on Friday morning, BidAskClub reports.

Several other brokerages have also recently commented on RARX. Robert W. Baird initiated coverage on shares of Ra Pharmaceuticals in a research note on Thursday, June 20th. They set an outperform rating for the company. Leerink Swann initiated coverage on shares of Ra Pharmaceuticals in a research note on Wednesday, May 22nd. They set an outperform rating and a $23.30 price objective for the company. SunTrust Banks lifted their price objective on shares of Ra Pharmaceuticals to $42.00 and gave the company a buy rating in a research note on Friday, May 17th. ValuEngine upgraded shares of Ra Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Tuesday, July 2nd. Finally, Raymond James cut shares of Ra Pharmaceuticals from a strong-buy rating to a market perform rating in a research note on Monday, July 29th. Three analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Ra Pharmaceuticals presently has a consensus rating of Buy and a consensus target price of $38.63.

Shares of NASDAQ RARX opened at $25.70 on Friday. The company has a current ratio of 15.30, a quick ratio of 15.30 and a debt-to-equity ratio of 0.02. Ra Pharmaceuticals has a 12 month low of $11.27 and a 12 month high of $36.96. The company has a 50 day simple moving average of $29.59 and a two-hundred day simple moving average of $25.92. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -12.48 and a beta of 1.37.

Ra Pharmaceuticals (NASDAQ:RARX) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.03). Analysts forecast that Ra Pharmaceuticals will post -1.97 EPS for the current year.

In related news, insider Alonso Ricardo sold 2,857 shares of the business’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $23.72, for a total value of $67,768.04. Following the completion of the transaction, the insider now directly owns 11,428 shares in the company, valued at approximately $271,072.16. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Ramin Farzaneh-Far sold 10,595 shares of the business’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $33.10, for a total transaction of $350,694.50. Following the completion of the transaction, the insider now owns 8,521 shares of the company’s stock, valued at $282,045.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 43,452 shares of company stock valued at $1,248,163. Company insiders own 4.30% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Group One Trading L.P. purchased a new stake in Ra Pharmaceuticals in the 1st quarter worth $34,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Ra Pharmaceuticals by 163.0% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,014 shares of the company’s stock worth $68,000 after acquiring an additional 1,868 shares in the last quarter. BNP Paribas Arbitrage SA purchased a new stake in Ra Pharmaceuticals in the 1st quarter worth $88,000. Bank of Montreal Can increased its holdings in Ra Pharmaceuticals by 218.0% in the 2nd quarter. Bank of Montreal Can now owns 3,832 shares of the company’s stock worth $115,000 after acquiring an additional 2,627 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in Ra Pharmaceuticals in the 1st quarter worth $229,000. Hedge funds and other institutional investors own 91.59% of the company’s stock.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

See Also: Why is momentum important to successful trading?

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SOTHERLY HOTELS/SH SH  Upgraded by Zacks Investment Research to Hold
SOTHERLY HOTELS/SH SH Upgraded by Zacks Investment Research to Hold
Solaredge Technologies  Lowered to Hold at Zacks Investment Research
Solaredge Technologies Lowered to Hold at Zacks Investment Research
Resonant  Upgraded to “Hold” at Zacks Investment Research
Resonant Upgraded to “Hold” at Zacks Investment Research
Portola Pharmaceuticals  PT Lowered to $44.00
Portola Pharmaceuticals PT Lowered to $44.00
UltraNote Coin Reaches Market Cap of $13,486.00
UltraNote Coin Reaches Market Cap of $13,486.00
FS KKR Capital Corp  Receives $7.63 Consensus PT from Analysts
FS KKR Capital Corp Receives $7.63 Consensus PT from Analysts


© 2006-2019 Ticker Report